Table 1.
Relationship between increases in bone resorption rate and fracture risk
| Study | Age (years) | Fracture | RR-BMD* | 95 % CI | Marker | RR-marker† | 95 % CI | |
|---|---|---|---|---|---|---|---|---|
| Women | EPIDOS( 74 ) | >75 | Hip | 2·8 | 1·6, 5·1 | Urinary CTX | 2·2 | 1·3, 3·6 |
| OFELY( 83 ) | 64 (mean) | All | 2·8 | 1·4, 5·6 | Urinary CTX | 2·3 | 1·3, 4·1 | |
| Serum CTX | 2·1 | 1·1, 3·6 | ||||||
| HOS( 84 ) | 69 (mean) | All | 1·6 | 1·2, 2·2 | Urinary CTX | 1·6 | 1·2, 2·0 | |
| Rotterdam( 85 ) | >75 | All | 1·3 | 0·6, 2·8 | Urinary DPD | 1·9 | 1·2, 3·8 | |
| Malmö OPRA( 86 ) | >75 | All | 2·2 | 1·5, 3·1 | TRAP | 2·2 | 1·2, 4·2 | |
| Men | DOES( 87 ) | 72 (mean) | All | 1·8 | 1·4, 2·3 | ICTP | 1·4 | 1·0, 1·9 |
| 2·8‡ | 1·4, 5·4 |
RR, relative risk; BMD, bone mineral density; EPIDOS, Epidemiology of Osteoporosis; CTX, carboxy terminal telopeptide of collagen type I; OFELY, Os de Femmes de Lyon; HOS, Hawaii Osteoporosis Study; DPD, free deoxypyridinoline; OPRA, Osteoporosis Prospective Risk Assessment; TRAP, tartrate-resistant acid phosphatase; DOES, Dubbo Osteoporosis Epidemiology Study; ICTP, C-terminal telopeptide generated by metalloproteinases.
*
RR-BMD = RR for fracture by 1 sd decrease in BMD.
†
RR-marker = RR for fracture by 1 sd increase in marker above the premenopausal normal range.
‡
For the highest quintile.